文献类型：期刊文献

中文题名：PD-1/PD-L1抑制剂与仑伐替尼联合用药的研究进展

英文题名：Research progress of combination therapy of PD-1/PD-L1 inhibitors and lenvatinib

作者：周艳艳[1];骆翔[1,2];朱柯武[1]

机构：[1]绍兴文理学院医学院新型药物递送系统及原料药研究中心,浙江绍兴312000;[2]绍兴文理学院化学化工学院脂溶性维生素浙江省工程研究中心,浙江绍兴312000

年份：2023

卷号：40

期号：11

起止页码：1530

中文期刊名：沈阳药科大学学报

外文期刊名：Journal of Shenyang Pharmaceutical University

收录：CSTPCD、、CSCD_E2023_2024、北大核心、CSCD、北大核心2020

基金：浙江省教育厅一般科研项目(Y202145959);绍兴文理学院校级重点科研项目(2020LG1002)。

语种：中文

中文关键词：PD-1/PD-L1抑制剂;仑伐替尼;联合用药;作用机制;临床应用

外文关键词：PD-1/PD-L1 inhibitors;lenvatinib;combination therapy;mechanism;clinical application

中文摘要：目的PD-1/PD-L1抑制剂作为最主要的免疫疗法药物,目前已成为临床上肿瘤治疗的重要手段。然而,PD-1/PD-L1抑制剂单独使用治疗肿瘤的有效率普遍低于30%,仑伐替尼单独用药时,仅对20%的肝癌患者的有效。临床前和临床研究已经指出联合阻断VEGF和抑制性免疫检查点信号,可增强免疫激活和肿瘤破坏。PD-1/PD-L1抑制剂与抗血管生成药物仑伐替尼联合用药在多种癌症治疗中已表现出较好的抗肿瘤能力,显著提高了PD-1/PD-L1抑制剂的疗效和应用范围。方法结合临床实验数据,并深入分析两种药物的作用靶点,简单阐明PD-1/PD-L1抑制剂与仑伐替尼联合用药作用机制。结果本文结合66篇国内外相关文献,针对PD-1/PD-L1抑制剂和仑伐替尼联用的最新临床应用研究进行综述。结论本综述将为PD-1/PD-L1抑制剂与仑伐替尼的联合用药提供更加完善的理论基础和实际应用指导。

外文摘要：Objective PD-1/PD-L1 inhibitors,as the most important immunotherapy drugs,have become an important means of clinical tumor treatment.However,PD-1/PD-L1 inhibitors alone are generally less than 30%effective in treating tumors,and lenvatinib alone is effective in only 20%of liver cancer patients.Preclinical and clinical studies have indicated that combined blockade of VEGF and inhibitory immune checkpoint signaling enhances immune activation and tumor destruction.The combination of PD-1/PD-L1 inhibitors and the anti-angiogenic drug lenvatinib has shown good anti-tumor ability in the treatment of various cancers,significantly improving the efficacy of PD-1/PD-L1 inhibitors and scope of application.Methods Combined with clinical experimental data and in-depth analysis of the targets of the two drugs,the action mechanism of the combination of PD-1/PD-L1 inhibitors and lenvatinib was briefly clarified.Results In this review,we combined 74 relevant literatures to address the latest clinical research on the combination of PD-1/PD-L1 inhibitors and lenvatinib.Conclusion The review will provide a more complete theoretical basis and practical guidance for the combination of PD-1/PD-L1 inhibitors and lenvatinib.